Literature DB >> 12028055

Hb H hydrops fetalis syndrome associated with the interaction of two common determinants of alpha thalassaemia (--MED/(alpha)TSaudi(alpha)).

Vip Viprakasit1, Sarah Green, Sue Height, Helena Ayyub, Douglas R Higgs.   

Abstract

To date, more than 35 single or oligonucleotide mutations of the alpha genes that cause alpha thalassaemia have been described. Their interactions give rise to widely variable clinical manifestations, from a mild hypochromic, microcytic anaemia to a lethal intrauterine anaemia associated with hydrops fetalis. Understanding the molecular genetics enables accurate genotyping, genetic counselling and prenatal testing for the most severe forms of alpha thalassaemia. Here we show for the first time that the interaction between two relatively common forms of alpha thalassaemia (--MED/(alpha)TSaudi(alpha)) may be associated with a clinically severe form of alpha thalassaemia, Hb H hydrops fetalis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028055     DOI: 10.1046/j.1365-2141.2002.03427.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

Review 1.  Alpha-thalassaemia.

Authors:  Cornelis L Harteveld; Douglas R Higgs
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

2.  Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign.

Authors:  Abdulrahman Alsultan; Mohammed K Alabdulaali; Paula J Griffin; Ahmed M Alsuliman; Hazem A Ghabbour; Paola Sebastiani; Waleed H Albuali; Amein K Al-Ali; David H K Chui; Martin H Steinberg
Journal:  Br J Haematol       Date:  2013-11-13       Impact factor: 6.998

3.  UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease.

Authors:  Zainab Hamad; Abdullah Aljedai; Rabih Halwani; Abdulrahman AlSultan
Journal:  Ann Saudi Med       Date:  2013 Jul-Aug       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.